380 related articles for article (PubMed ID: 34659082)
61. Granzyme B in peripheral blood mononuclear cells as a measure of cell-mediated immune response in paraneoplastic neurological syndromes and malignancy.
Zaborowski MP; Stefens-Stawna P; Osztynowicz K; Piorunek T; Batura-Gabryel H; Dyzmann-Sroka A; Kozubski W; Nowak-Markwitz E; Michalak S
Cancer Immunol Immunother; 2021 May; 70(5):1277-1289. PubMed ID: 33136178
[TBL] [Abstract][Full Text] [Related]
62. Paraneoplastic sensitive neuropathy associated with anti-hu antibodies in a neuroendocrine tumor of duodenum: a case report.
Nappi L; Formisano L; Damiano V; Matano E; Bianco R; Tortora G
Int J Immunopathol Pharmacol; 2010; 23(4):1281-5. PubMed ID: 21244780
[TBL] [Abstract][Full Text] [Related]
63. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies.
Dubey D; David WS; Amato AA; Reynolds KL; Clement NF; Chute DF; Cohen JV; Lawrence DP; Mooradian MJ; Sullivan RJ; Guidon AC
Neurology; 2019 Sep; 93(11):e1093-e1103. PubMed ID: 31405908
[TBL] [Abstract][Full Text] [Related]
64. Pain as a First Manifestation of Paraneoplastic Neuropathies: A Systematic Review and Meta-Analysis.
Zis P; Paladini A; Piroli A; McHugh PC; Varrassi G; Hadjivassiliou M
Pain Ther; 2017 Dec; 6(2):143-151. PubMed ID: 28669085
[TBL] [Abstract][Full Text] [Related]
65. Anti-Ma2 Antibody-Associated Paraneoplastic Neurological Syndromes: A Pilot Study.
Guo Y; Cai MT; Lai QL; Zheng Y; Shen CH; Zhang YX
Brain Sci; 2021 Nov; 11(12):. PubMed ID: 34942879
[TBL] [Abstract][Full Text] [Related]
66. Recommended diagnostic criteria for paraneoplastic neurological syndromes.
Graus F; Delattre JY; Antoine JC; Dalmau J; Giometto B; Grisold W; Honnorat J; Smitt PS; Vedeler Ch; Verschuuren JJ; Vincent A; Voltz R
J Neurol Neurosurg Psychiatry; 2004 Aug; 75(8):1135-40. PubMed ID: 15258215
[TBL] [Abstract][Full Text] [Related]
67. Antiganglioside antibodies in paraneoplastic peripheral neuropathies.
Antoine JC; Camdessanché JP; Ferraud K; Caudie C
J Neurol Neurosurg Psychiatry; 2004 Dec; 75(12):1765-7. PubMed ID: 15548502
[TBL] [Abstract][Full Text] [Related]
68. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy.
Antoine JC; Honnorat J; Camdessanché JP; Magistris M; Absi L; Mosnier JF; Petiot P; Kopp N; Michel D
Ann Neurol; 2001 Feb; 49(2):214-21. PubMed ID: 11220741
[TBL] [Abstract][Full Text] [Related]
69. Peripheral nervous system manifestations of Sjögren syndrome: clinical patterns, diagnostic paradigms, etiopathogenesis, and therapeutic strategies.
Birnbaum J
Neurologist; 2010 Sep; 16(5):287-97. PubMed ID: 20827117
[TBL] [Abstract][Full Text] [Related]
70. Antinuclear antibodies define a subgroup of paraneoplastic neuropathies: clinical and immunological data.
Tschernatsch M; Stolz E; Strittmatter M; Kaps M; Blaes F
J Neurol Neurosurg Psychiatry; 2005 Dec; 76(12):1702-6. PubMed ID: 16291897
[TBL] [Abstract][Full Text] [Related]
71. [Diagnosis of immune-mediated neuropathies].
Diószeghy P
Orv Hetil; 2011 Sep; 152(39):1560-8. PubMed ID: 21920842
[TBL] [Abstract][Full Text] [Related]
72. Clinicopathologic Findings in Patients With Paraneoplastic Neuropathies and Antibodies Strongly Associated With Cancer.
Granger A; Rajnauth T; Lahoria R; Dubey D; Mills J; Mauermann ML; Berini SE; Spinner RJ; Dyck PJB; Klein CJ
Neurology; 2024 Jan; 102(2):e207982. PubMed ID: 38165318
[TBL] [Abstract][Full Text] [Related]
73. Antibody testing in peripheral nerve disorders.
Steck A; Yuki N; Graus F
Handb Clin Neurol; 2013; 115():189-212. PubMed ID: 23931781
[TBL] [Abstract][Full Text] [Related]
74. [Paraneoplastic neurological syndrome--definition and history].
Inuzuka T
Brain Nerve; 2010 Apr; 62(4):301-8. PubMed ID: 20420169
[TBL] [Abstract][Full Text] [Related]
75. Paraneoplastic neurologic syndromes in children: a review article.
Alavi S
Iran J Child Neurol; 2013; 7(3):6-14. PubMed ID: 24665300
[TBL] [Abstract][Full Text] [Related]
76. Onconeural antibodies in patients with neurological symptoms: detection and clinical significance.
Raspotnig M; Vedeler CA; Storstein A
Acta Neurol Scand Suppl; 2011; (191):83-8. PubMed ID: 21711262
[TBL] [Abstract][Full Text] [Related]
77. Treatment options in paraneoplastic disorders of the peripheral nervous system.
Antoine JC; Camdessanché JP
Curr Treat Options Neurol; 2013 Apr; 15(2):210-23. PubMed ID: 23307613
[TBL] [Abstract][Full Text] [Related]
78. [Clinical analysis of 11 cases of lymphoma complicated with paraneoplastic neurological syndrome].
Wei C; Zhao DQ; Zhang Y; Wang W; Zhang W; Zhou DB
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):311-315. PubMed ID: 35680630
[No Abstract] [Full Text] [Related]
79. Paraneoplastic neurological syndrome: an evolving story.
Jitprapaikulsan J; Paul P; Thakolwiboon S; Mittal SO; Pittock SJ; Dubey D
Neurooncol Pract; 2021 Aug; 8(4):362-374. PubMed ID: 34277016
[TBL] [Abstract][Full Text] [Related]
80. The Importance of Rare Subtypes in Diagnosis and Treatment of Peripheral Neuropathy: A Review.
Callaghan BC; Price RS; Chen KS; Feldman EL
JAMA Neurol; 2015 Dec; 72(12):1510-8. PubMed ID: 26437251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
